Robin Jones to Cardiovascular Diseases
This is a "connection" page, showing publications Robin Jones has written about Cardiovascular Diseases.
Connection Strength
1.101
-
A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Oct; 76(4):777-84.
Score: 0.384
-
Cardio-oncology: a special focus issue from Future Oncology. Future Oncol. 2015; 11(14):1993-4.
Score: 0.368
-
Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther. 2006 Sep; 6(9):1249-69.
Score: 0.206
-
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Med. 2021 06; 10(11):3565-3574.
Score: 0.143